Despite the clinical utility of biomarker testing in patients with prostate cancer, the tests are infrequently ordered, preventing optimized care. Despite guideline recommendations and the efficacy of ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

Please provide your email address to receive an email when new articles are posted on . Biomarker testing appeared inconsistent, with rates not reflecting guidelines. Less than 25% of oncologists ...

Although treatment of advanced gastroesophageal cancer is increasingly dependent on biomarkers, only about 40% of patients are tested. For patients to fully benefit from the latest targeted therapies, ...

Exact Science’s Michelle Beidelschies, PhD, reveals how a multi-biomarker class multi-cancer early detection test (MCED) blood test can help health systems expand detection across more cancers earlier ...

Nearly one-third of eligible stage IV nonsquamous NSCLC patients lack biomarker testing, with disparities among older adults, males, and lower socioeconomic groups. Oncologist education is crucial to ...

Over 20% of high-grade serous ovarian cancer patients have BRCA mutations, and up to 50% exhibit HRD, impacting DNA repair pathways. Global guidelines recommend BRCA and HRD testing, but many eligible ...

Lung cancer remains the leading cause of cancer deaths in Virginia, according to a new report from the American Lung Association. The 2025 “State of Lung Cancer” report for Virginia found in most ...

CHICAGO, Nov. 19, 2024 /PRNewswire/ -- Lung cancer is the leading cause of the cancer deaths in the U.S., but the American Lung Association's 2024 "State of Lung Cancer" report reveals positive news.

BeiGene is back with a new partnership and oncology campaign to raise awareness about biomarker testing for patients with chronic lymphocytic leukemia (CLL), a blood cancer marked by the ...

As tests and screenings for chronic conditions improve, Connecticut residents will have better access after lawmakers passed legislation mandating health insurance plans cover biomarker tests starting ...